Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Treasury Shares (2020 - 2025)

10x Genomics' Treasury Shares history spans 6 years, with the latest figure at $7.8 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 20.53% year-over-year to $7.8 million; the TTM value through Dec 2025 reached $7.8 million, up 20.53%, while the annual FY2025 figure was $7.8 million, 20.53% up from the prior year.
  • Treasury Shares for Q4 2025 was $7.8 million at 10x Genomics, down from $8.5 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $9.2 million in Q2 2025 and bottomed at $985386.0 in Q1 2021.
  • The 5-year median for Treasury Shares is $5.8 million (2022), against an average of $5.1 million.
  • The largest annual shift saw Treasury Shares soared 1591.53% in 2021 before it dropped 8.6% in 2023.
  • A 5-year view of Treasury Shares shows it stood at $1.3 million in 2021, then soared by 349.55% to $5.8 million in 2022, then decreased by 8.6% to $5.3 million in 2023, then rose by 21.73% to $6.5 million in 2024, then increased by 20.53% to $7.8 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Treasury Shares are $7.8 million (Q4 2025), $8.5 million (Q3 2025), and $9.2 million (Q2 2025).